Back to Journals
Pragmatic and Observational Research
Professor David Price
Founder and Head of The Observational and Pragmatic Research Institute, Observational and Pragmatic Research Institute, Singapore
Professor Price is Primary Care Respiratory Society Professor of Primary Care Respiratory Medicine at the University of Aberdeen (UK). He was awarded Fellow of ERS (FERS) in 2016. He is also a member of the World Health Organization (WHO) Allergic Rhinitis and its Impact on Asthma (ARIA) executive committee, the World Allergy Organization (WAO) Committee on Asthma, and the WAO Education Council. Professor Price was the founding president of the Respiratory Effectiveness Group (REG), a not-for-profit, investigator-led initiative which uses an international collaborative approach to explore the optimum role of real-life research in informing clinical guidelines and improving patient care. He completed his medical degree at Cambridge University in 1984. He was previously Affiliate Associate Professor in the Department of General Practice at the University of Adelaide, Australia and held an Honorary Chair at the University of East Anglia, UK.
The Founder and Head of The Observational and Pragmatic Research Institute (OPRI) Singapore, an independent, research-driven organisation established to cultivate initiatives, provide evidence, and drive quality standards within the growing field of real-life, pragmatic, and observational research. This dynamic organisation delivers pragmatic clinical trials and real-life database research across multiple geographies, including territories in the United States, Europe, and the Asia-Pacific region, such as Singapore, South Korea, Taiwan, The Philippines, New Zealand, Australia, Japan, and China.
The Head of Optimum Patient Care (OPC) Global, Australia and UK, a social enterprise which focuses on disease registries and quality improvement in primary and secondary care led by internationally recognised experts in all areas of respiratory medicine. Professor Price established the Optimum Patient Care Research Database (OPCRD), one of the largest enhanced healthcare databases holding anonymous data from over 1000 general practices and approximately 18 million patients in the UK.
He currently leads the first International Severe Asthma Registry (ISAR) by creating a consortium of world leaders at the forefront of severe asthma research from over 30 countries. His efforts have unified the severe asthma world by creating a vibrant space to exchange ideas and by standardising the data fields across countries, which is enabling data to be pooled and shared.
He leads the COllaboratioN on QUality improvement initiative for achieving Excellence in Standards of COPD care (CONQUEST), a novel, collaborative, interventional COPD registry. It comprises an integrated quality improvement program focusing on patients (diagnosed and undiagnosed) at a modifiable and higher risk of COPD exacerbations. CONQUEST is underpinned by 4-evidence based Quality Standards developed by 11 experts internationally recognized in their field and drives long-term, targeted, patient-centred changes in COPD management. The promotion of expert and guideline-led care aims to reduce exacerbation frequency and improve health care outcomes.
He is extensively involved in respiratory and allergy research; his areas of special interest are the ‘real-life’ effectiveness and cost-effectiveness of interventions, clinical trial design, adherence, and patient attitudes to their disease. He has authored over 888 peer-reviewed publications since 2000 with a H-index of 103 and responsible for approximately US$75 million in research and clinical development grants. He is currently Editor-in-Chief of the journal Pragmatic and Observational Research and member of the editorial board of several respiratory journals, including The Lancet Respiratory Medicine.
Dr Gonzalez de la Parra
Mario Gonzalez de la Parra, Scientific Director, Biokinetics, S.A. de C.V, Mexico City, Mexico.
John Haughney, Associate Director, Clinical R&D, NHS Greater Glasgow and Clyde, Glasgow UK; Senior Research fellow, University of Aberdeen, Aberdeen UK
Sabzali Javadov, Professor, Department of Physiology, School of Medicine, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, USA.
Amanda Lee, Director of Institute of Applied Health Sciences, School of Medicine, Medical Sciences & Nutrition, University of Aberdeen, Aberdeen, Scotland, UK.
Kyu Lim, Professor, Department of Biochemistry, College of Medicine, Cancer Research Institute, Infection Signaling Network Research Center, Chungnam National University, Korea.
Christoph R. Meier, Professor, Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Switzerland
Arshag D. Mooradian, Professor of Medicine, Chairman, Department of Medicine, University of Florida, Jacksonville, Florida, USA.
Emilio Perucca, Professor of Pharmacology, University of Pavia, Director of the Clinical Trial Centre at the Institute of Neurology IRCCS C. Mondino Foundation, Pavia, Italy.
Dr van Boven
Dr Job FM van Boven, Associate Professor of Health Economics & Real-World (drug) Outcomes, Department of Clinical Pharmacy & Pharmacology, Groningen Research Institute for Asthma and COPD (GRIAC), University Medical Centre Groningen, University of Groningen, The Netherlands.